SC
COGT icon

SummitTX Capital’s Cogent Biosciences COGT Stock Holding History

SummitTX Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.96M Sell
179,734
-114,046
-39% -$3.99M 0.18% 143
2026
Q1 		$11.3M Buy
293,780
+36,609
+14% +$1.35M 0.35% 50
2025
Q4 		$9.13M Sell
257,171
-38,639
-13% -$1.09M 0.28% 82
2025
Q3 		$4.25M Sell
295,810
-4,129
-1% -$48.9K 0.18% 131
2025
Q2 		$2.15M Buy
299,939
+2,811
+0.9% +$15.6K 0.09% 239
2025
Q1 		$1.78M Buy
+297,128
New +$2.33M 0.08% 273

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SummitTX Capital's COGT Position: Q2 2026 in Review

SummitTX Capital reduced its Cogent Biosciences (COGT) stake by 39% in Q2 2026, selling an estimated $3.99M and leaving 179,734 shares worth $6.96M. The position accounts for 0.18% of the portfolio, ranked #143.

SummitTX Capital first reported a position in COGT in Q1 2025 and has held it in 6 quarters since. The position peaked at $11.3M in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • SummitTX Capital held 179,734 shares of Cogent Biosciences worth $6.96M as of Q2 2026.
  • SummitTX Capital sold 114,046 Cogent Biosciences shares in Q2 2026, an estimated $3.99M.
  • Cogent Biosciences made up 0.18% of SummitTX Capital's portfolio in Q2 2026, its #143 holding.
  • SummitTX Capital first reported a position in Cogent Biosciences in Q1 2025 and has held it in 6 quarters since.
  • SummitTX Capital's Cogent Biosciences position peaked at $11.3M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.